A Mechanistic Model for Paradoxical Platelet Activation by
Ligand-Mimetic αIIbβ3 (GPIIb/IIIa) Antagonists
by Nicole Bassler, Christoph Loeffler, Pierre Mangin, Yuping Yuan, Meike Schwarz,
Christoph E. Hagemeyer, Steffen U. Eisenhardt, Ingo Ahrens, Christoph Bode,
Shaun P. Jackson, and Karlheinz Peter
Arterioscler Thromb Vasc Biol
Volume 27(3):E9-E15
March 1, 2007
Copyright © American Heart Association, Inc. All rights reserved.
Figure 1. The combination of conformational change of αIIbβ3 (induced by ligand-mimetic
blockers or an anti-LIBS antibody), αIIbβ3 crosslinking, and preactivation (low dose ADP) results
in strong platelet activation.
Nicole Bassler et al. Arterioscler Thromb Vasc Biol.
2007;27:E9-E15
Copyright © American Heart Association, Inc. All rights reserved.
Figure 2. Adhesion of platelets to collagen is sufficient to result in paradoxical platelet activation
by ligand-mimetic αIIbβ3 antagonists.
Nicole Bassler et al. Arterioscler Thromb Vasc Biol.
2007;27:E9-E15
Copyright © American Heart Association, Inc. All rights reserved.
Figure 3. Ca2+ measurements report on αIIbβ3 antagonist-induced platelet activation.
Nicole Bassler et al. Arterioscler Thromb Vasc Biol.
2007;27:E9-E15
Copyright © American Heart Association, Inc. All rights reserved.
Figure 4. Mechanistic model of paradoxical platelet activation by ligand-mimetic αIIbβ3
antagonists.
Nicole Bassler et al. Arterioscler Thromb Vasc Biol.
2007;27:E9-E15
Copyright © American Heart Association, Inc. All rights reserved.